JP2012197278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012197278A5 JP2012197278A5 JP2012091882A JP2012091882A JP2012197278A5 JP 2012197278 A5 JP2012197278 A5 JP 2012197278A5 JP 2012091882 A JP2012091882 A JP 2012091882A JP 2012091882 A JP2012091882 A JP 2012091882A JP 2012197278 A5 JP2012197278 A5 JP 2012197278A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- antigen
- binding portion
- tumor cells
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05011536.9 | 2005-05-27 | ||
| EP05011536A EP1726650A1 (en) | 2005-05-27 | 2005-05-27 | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512701A Division JP5038297B2 (ja) | 2005-05-27 | 2006-03-02 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014017392A Division JP6110321B2 (ja) | 2005-05-27 | 2014-01-31 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012197278A JP2012197278A (ja) | 2012-10-18 |
| JP2012197278A5 true JP2012197278A5 (enExample) | 2013-12-05 |
| JP5524270B2 JP5524270B2 (ja) | 2014-06-18 |
Family
ID=34937022
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512701A Expired - Lifetime JP5038297B2 (ja) | 2005-05-27 | 2006-03-02 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
| JP2012091882A Expired - Lifetime JP5524270B2 (ja) | 2005-05-27 | 2012-04-13 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
| JP2014017392A Expired - Lifetime JP6110321B2 (ja) | 2005-05-27 | 2014-01-31 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
| JP2016063219A Pending JP2016190839A (ja) | 2005-05-27 | 2016-03-28 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512701A Expired - Lifetime JP5038297B2 (ja) | 2005-05-27 | 2006-03-02 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014017392A Expired - Lifetime JP6110321B2 (ja) | 2005-05-27 | 2014-01-31 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
| JP2016063219A Pending JP2016190839A (ja) | 2005-05-27 | 2016-03-28 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8198416B2 (enExample) |
| EP (3) | EP1726650A1 (enExample) |
| JP (4) | JP5038297B2 (enExample) |
| CN (1) | CN101233236B (enExample) |
| AT (1) | ATE505544T1 (enExample) |
| AU (1) | AU2006251445B2 (enExample) |
| CA (1) | CA2609682C (enExample) |
| CY (1) | CY1111409T1 (enExample) |
| DE (1) | DE602006021296D1 (enExample) |
| DK (1) | DK1883698T4 (enExample) |
| ES (1) | ES2362795T5 (enExample) |
| PL (1) | PL1883698T5 (enExample) |
| PT (1) | PT1883698E (enExample) |
| RU (1) | RU2458073C2 (enExample) |
| SI (1) | SI1883698T2 (enExample) |
| WO (1) | WO2006125481A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| JP5355839B2 (ja) | 2001-10-23 | 2013-11-27 | ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． | Ｐｓｍａ抗体およびタンパク質マルチマー |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| GB0715542D0 (en) * | 2007-08-09 | 2007-09-19 | Imp Innovations Ltd | Methods |
| BRPI0819598A2 (pt) | 2007-11-30 | 2017-05-09 | Kalobios Pharmaceuticals Inc | anticorpos para o antígeno pcrv da pseudomonas aeruginosa |
| US20110189093A1 (en) * | 2008-04-14 | 2011-08-04 | Proscan Rx Pharma | Prostate specific membrane antigen antibodies and antigen binding fragments |
| ITTO20080313A1 (it) * | 2008-04-22 | 2009-10-23 | Marco Colombatti | Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi |
| US20110293619A1 (en) | 2008-10-01 | 2011-12-01 | Micromet Ag | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY |
| DK2352763T4 (da) | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| ES2712732T3 (es) * | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
| TWI629357B (zh) * | 2009-10-02 | 2018-07-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種特異性的ＰＳＭＡｘＣＤ３雙特異性單鏈抗體 |
| AU2010325969B2 (en) * | 2009-12-02 | 2016-10-20 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| EP2699596A4 (en) | 2011-04-22 | 2015-01-14 | Emergent Product Dev Seattle | PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR |
| WO2013155605A1 (en) * | 2012-04-19 | 2013-10-24 | Innovascreen Inc. | Method for predicting a pathophysiological condition in an animal |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| FI3380620T3 (fi) | 2015-11-23 | 2024-08-01 | Novartis Ag | Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja |
| RU2018127657A (ru) | 2015-12-30 | 2020-01-31 | Новартис Аг | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью |
| CN105542009A (zh) * | 2016-02-03 | 2016-05-04 | 南昌大学 | 一种针对前列腺特异性膜抗原的单域重链抗体 |
| CN105524171A (zh) * | 2016-02-03 | 2016-04-27 | 中国人民解放军第三军医大学第三附属医院 | 一种针对前列腺特异性膜抗原的纳米抗体 |
| CN105504061A (zh) * | 2016-02-03 | 2016-04-20 | 南昌大学 | 针对前列腺特异性膜抗原的纳米抗体 |
| CN105968202A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 针对前列腺特异性膜抗原胞外区的单域重链抗体 |
| CN105968201A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 针对前列腺特异性膜抗原的单域重链抗体 |
| CN105968203A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 一种抗前列腺特异性膜抗原胞外区的单域重链抗体 |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| CN109715808A (zh) | 2016-04-15 | 2019-05-03 | 诺华股份有限公司 | 用于选择性蛋白质表达的组合物和方法 |
| WO2017201493A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single chain variable fragment cd3 binding proteins |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| BR112019002035A2 (pt) | 2016-08-01 | 2019-05-14 | Novartis Ag | tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2 |
| AU2017363300A1 (en) * | 2016-11-23 | 2019-06-20 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
| WO2018098356A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Psma targeting trispecific proteins and methods of use |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| AU2018351050B2 (en) | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| RU2020116579A (ru) | 2017-10-25 | 2021-11-25 | Новартис Аг | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
| US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
| KR20200098590A (ko) | 2017-12-12 | 2020-08-20 | 마크로제닉스, 인크. | 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도 |
| JP2021521202A (ja) | 2018-04-13 | 2021-08-26 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 固形腫瘍の治療のための標的化されたアマトキシン複合体 |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| BR112020023330A2 (pt) | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3587454A1 (en) * | 2018-06-27 | 2020-01-01 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| IL279823B2 (en) * | 2018-07-31 | 2026-02-01 | Heidelberg Pharma Res Gmbh | Cultured antibodies against psma |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN110407939B (zh) * | 2019-03-12 | 2023-09-29 | 广东医科大学附属第二医院 | 一种人源化抗psma单链抗体及其应用 |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| AU2020275002A1 (en) | 2019-05-14 | 2021-12-23 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| EP3842461A1 (en) | 2019-12-23 | 2021-06-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
| CN111303288B (zh) * | 2020-03-04 | 2020-12-25 | 和铂医药(苏州)有限公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| WO2021164692A1 (zh) * | 2020-02-18 | 2021-08-26 | 和铂医药(上海)有限责任公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| CN115768463A (zh) | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | Flt3结合蛋白及使用方法 |
| JP2023529211A (ja) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Ｚｂｔｂ３２阻害剤及びその使用 |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| KR20230042035A (ko) | 2020-07-08 | 2023-03-27 | 라바 테라퓨틱스 엔.브이. | Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체 |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
| CN119735685B (zh) * | 2025-03-04 | 2025-06-13 | 深圳真实生物医药科技有限公司 | 一种靶向前列腺特异性膜抗原的抗体、其抗原结合片段、制备方法及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| DK0682710T3 (da) * | 1993-02-10 | 2004-03-01 | Unilever Nv | Isolationsmetode, ved hvilken der anvendes immobiliserede proteiner med specifikke kapaciteter |
| US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| EP0914155B1 (en) * | 1996-03-25 | 2006-02-22 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| NZ337048A (en) * | 1997-02-26 | 2000-10-27 | Sankyo Co | Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer |
| US6258939B1 (en) * | 1997-03-10 | 2001-07-10 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
| NZ517331A (en) * | 1999-07-29 | 2004-02-27 | Medarex Inc | Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody |
| FR2797743B1 (fr) * | 1999-08-23 | 2003-08-08 | Urogene | Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal |
| WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| JP2005518336A (ja) * | 2001-06-26 | 2005-06-23 | イムクローン システムズ インコーポレイティド | Ｖｅｇｆ受容体に結合する二重特異性抗体 |
| EP1427377A4 (en) * | 2001-09-20 | 2006-04-12 | Cornell Res Foundation Inc | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISORDERS USING SPECIFIC BINDING AGENTS FOR A PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| JP5355839B2 (ja) * | 2001-10-23 | 2013-11-27 | ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． | Ｐｓｍａ抗体およびタンパク質マルチマー |
| CA2474616A1 (en) * | 2002-01-28 | 2003-08-07 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| JP2004000045A (ja) * | 2002-05-31 | 2004-01-08 | Kyowa Hakko Kogyo Co Ltd | 前立腺特異的膜抗原に対する抗体 |
| US6641899B1 (en) * | 2002-11-05 | 2003-11-04 | International Business Machines Corporation | Nonlithographic method to produce masks by selective reaction, articles produced, and composition for same |
| EP2336189A1 (en) * | 2003-01-28 | 2011-06-22 | Proscan RX Pharma | Prostate cancer diagnosis and treatment |
| EP1841467A4 (en) * | 2005-01-14 | 2009-01-28 | Cytogen Corp | COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES |
| JP2008529556A (ja) * | 2005-02-18 | 2008-08-07 | メダレックス， インク． | 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体 |
| CN101160324B (zh) * | 2005-02-18 | 2013-04-24 | 米德列斯公司 | 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体 |
| WO2006110745A2 (en) * | 2005-04-08 | 2006-10-19 | Cytogen Corporation | Conjugated anti-psma antibodies |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| DK1912677T3 (da) * | 2005-06-20 | 2014-01-13 | Psma Dev Company L L C | PSMA-antistof-lægemiddel-konjugater |
-
2005
- 2005-05-27 EP EP05011536A patent/EP1726650A1/en not_active Withdrawn
-
2006
- 2006-03-02 DE DE602006021296T patent/DE602006021296D1/de not_active Expired - Lifetime
- 2006-03-02 SI SI200630996T patent/SI1883698T2/sl unknown
- 2006-03-02 CN CN2006800275807A patent/CN101233236B/zh not_active Expired - Lifetime
- 2006-03-02 PL PL06707388T patent/PL1883698T5/pl unknown
- 2006-03-02 PT PT06707388T patent/PT1883698E/pt unknown
- 2006-03-02 US US11/915,454 patent/US8198416B2/en not_active Expired - Lifetime
- 2006-03-02 AU AU2006251445A patent/AU2006251445B2/en not_active Expired
- 2006-03-02 DK DK06707388.2T patent/DK1883698T4/en active
- 2006-03-02 EP EP06707388.2A patent/EP1883698B2/en not_active Expired - Lifetime
- 2006-03-02 CA CA2609682A patent/CA2609682C/en not_active Expired - Lifetime
- 2006-03-02 WO PCT/EP2006/001917 patent/WO2006125481A1/en not_active Ceased
- 2006-03-02 RU RU2007147596/10A patent/RU2458073C2/ru active
- 2006-03-02 EP EP11151622A patent/EP2363486A1/en not_active Ceased
- 2006-03-02 AT AT06707388T patent/ATE505544T1/de active
- 2006-03-02 ES ES06707388.2T patent/ES2362795T5/es not_active Expired - Lifetime
- 2006-03-02 JP JP2008512701A patent/JP5038297B2/ja not_active Expired - Lifetime
-
2011
- 2011-05-04 CY CY20111100431T patent/CY1111409T1/el unknown
-
2012
- 2012-04-13 JP JP2012091882A patent/JP5524270B2/ja not_active Expired - Lifetime
- 2012-05-08 US US13/466,286 patent/US8632777B2/en not_active Expired - Lifetime
-
2013
- 2013-12-13 US US14/105,808 patent/US9238694B2/en active Active
-
2014
- 2014-01-31 JP JP2014017392A patent/JP6110321B2/ja not_active Expired - Lifetime
-
2016
- 2016-03-28 JP JP2016063219A patent/JP2016190839A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012197278A5 (enExample) | ||
| PH12021551720A1 (en) | Dll3 targeting chimeric antigen receptors and binding agents | |
| CN113316591A (zh) | Cd73抗体及其制备方法和应用 | |
| HK1210620A1 (en) | Multi-specific monoclonal antibodies | |
| MY207205A (en) | Cd3 antibody and pharmaceutical use thereof | |
| MX2022015823A (es) | Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos. | |
| HK1207398A1 (en) | Cd3 binding polypeptides | |
| HK1199837A1 (en) | Humanized antibodies to inkt | |
| WO2012088247A3 (en) | Anti-c5/c5a/c5adesr antibodies and fragments | |
| RU2017132160A (ru) | Антитела к pd-l1 и их применение для усиления функции t-клеток | |
| EA201491524A1 (ru) | Связывающиеся с эритроцитами терапевтические средства | |
| MX359384B (es) | Conjunto mejorado de anticuerpos bisespecificos. | |
| WO2015092024A3 (en) | Method of engineering multi-input signal sensitive t cell for immunotherapy | |
| WO2015054691A8 (en) | Tem8 antibodies and their use | |
| EA201790175A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
| CR20110577A (es) | Proteínas de unión a il-1 | |
| CL2014000574A1 (es) | Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. | |
| NZ623086A (en) | Therapeutic peptides | |
| WO2012047732A3 (en) | Antibody compositions and methods of use | |
| EP4253959A3 (en) | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| EA201500502A1 (ru) | Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3 | |
| WO2011108008A3 (en) | Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1 | |
| HK1198832A1 (en) | Fn14 binding proteins and uses thereof | |
| WO2013142300A3 (en) | Jcv neutralizing antibodies |